Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: This year’s National Health Interview Survey was the first to ask about sexual orientation in addition to health habits in its 57-year history, the U.S. Centers for Disease Control and Prevention said. Bisexual women were twice as likely to experience serious anxiety while bisexual men were more likely to indulge in binge drinking than others, according to the survey. In the survey of more than 34,500 Americans age 18 and above, 1.6 percent reported that they were gay and 0.7 percent reported that they were bisexual. A total of 96.6 percent reported being straight and 1.1 percent either said they were “something else,” did not know or declined to answer. Roughly twice as many women than men identified as bisexual, with 0.9 percent of female respondents saying they were attracted to both sexes. Bisexual women were twice as likely to report having serious anxiety than any other group, with almost 11 percent saying they had been distressed in the past month. Among bisexual men, almost 52 percent said they had five drinks or more in a night during the past year compared with only 31 percent of straight men. Gays and bisexuals fared as well or better than their straight peers in some areas, like exercising, taking HIV tests and receiving flu vaccines. “The differences went both ways, and it depends on the specific indicator that you were looking at,” said Brian Ward, a lead author on the survey and health statistician for the CDC’s statistical arm. The CDC said the survey findings were in line with other  research on health and sexual orientation, though a smaller proportion of people in this survey identified as bisexual than in other studies.
Example Output: Government report finds 2.3 percent of Americans gay or bisexual.

Example Input: The verdict in the lawsuit brought by the California woman, Eva Echeverria, marks the largest sum awarded in a series of talcum powder lawsuit verdicts against Johnson & Johnson in courts around the U.S. Echeverria alleged Johnson & Johnson failed to adequately warn consumers about talcum powder’s potential cancer risks. She used the company’s baby powder on a daily basis beginning in the 1950s until 2016 and was diagnosed with ovarian cancer in 2007, according to court papers. Echeverria developed ovarian cancer as a “proximate result of the unreasonably dangerous and defective nature of talcum powder,” she said in her lawsuit. Echeverria’s attorney, Mark Robinson, said his client is undergoing cancer treatment while hospitalized and told him she hoped the verdict would lead Johnson & Johnson to put additional warnings on its products. “Mrs. Echeverria is dying from this ovarian cancer and she said to me all she wanted to do was to help the other women throughout the whole country who have ovarian cancer for using Johnson & Johnson for 20 and 30 years,” Robinson said. “She really didn’t want sympathy,” he added. “She just wanted to get a message out to help these other women.” The jury’s award included $68 million in compensatory damages and $340 million in punitive damages, Robinson said. The evidence in the case included internal documents from several decades that “showed the jury that Johnson & Johnson knew about the risks of talc and ovarian cancer,” Robinson said. “Johnson & Johnson had many warning bells over a 30 year period but failed to warn the women who were buying its product,” he said. Johnson & Johnson spokeswoman Carol Goodrich said in a statement that the company will appeal the jury’s decision. She says while the company sympathizes with women suffering from ovarian cancer that scientific evidence supports the safety of Johnson’s baby powder. The verdict came after a St. Louis, Missouri jury in May awarded $110.5 million to a Virginia woman who was diagnosed with ovarian cancer in 2012. She had blamed her illness on her use of the company’s talcum powder-containing products for more than 40 years. Besides that case, three other trials in St. Louis had similar outcomes last year — with juries awarding damages of $72 million, $70.1 million and $55 million, for a combined total of $307.6 million. Another St. Louis jury in March rejected the claims of a Tennessee woman with ovarian and uterine cancer who blamed talcum powder for her cancers. Two similar cases in New Jersey were thrown out by a judge who said the plaintiffs’ lawyers did not presented reliable evidence linking talc to ovarian cancer. More than 1,000 other people have filed similar lawsuits. Some who won their lawsuits won much lower amounts, illustrating how juries have wide latitude in awarding monetary damages. Johnson & Johnson is preparing to defend itself and its baby powder at upcoming trials in the U.S., Goodrich said. ___ Associated Press writer Amanda Lee Myers contributed to this report. ___ Follow Michael Balsamo on Twitter at http://twitter.com/MikeBalsamo1 .
Example Output: Record $417M award in lawsuit linking baby powder to cancer.

Example Input: Doctors and investors alike have been anxious to see how the experimental combination of dolutegravir and lamivudine, also known as 3TC, would stack up against highly effective triple drugs championed by arch-rival Gilead Sciences. GSK’s majority-owned ViiV Healthcare unit, which is responsible for HIV medicine, had reported success from the two so-called GEMINI studies last month but details were only unveiled at the International AIDS Conference in Amsterdam. Pedro Cahn, a veteran HIV researcher from Argentina who led the GEMINI studies, said the results showed it was possible get the efficacy of three drugs in a two-drug regimen. After studying 1,400 patients for 48 weeks, researchers found 91 percent of patients taking dolutegravir and lamivudine had high levels of viral control versus 93 percent of those on three drugs. The difference was not statistically significant. Rates of virologic failure, or inability to control HIV, were consistent at no more than 1 percent across all groups and no patients developed drug resistance. Importantly, the results were also broadly consistent whether individuals had higher or lower starting levels of HIV in their blood, reassuring those who had worried the two-drug regimen might work less well in people with more virus. “This is a new option for treatment,” Cahn said. “The main reason for doing this is to reduce the amount of drug burden when patients are on life-long treatment.”  GSK is betting that a shift to using two drugs rather than three will boost its sales by offering patients a therapy with fewer potentially toxic side effects. A two-drug regimen should also be cheaper, since lamivudine is an off-patent generic. ViiV has set itself a goal of overtaking Gilead in the $26 billion-a-year HIV market by the mid-2020s - an ambitious target, since Gilead currently has a market share of 52 percent against GSK’s 22 percent. Linda-Gail Bekker, an HIV expert at the University of Cape Town, who was not involved in the studies, said two-drug treatment was attractive in principle. “Simplification of treatment is what people want to see, both to reduce costs and to reduce side effects,” she told Reuters. Nearly half of all HIV patients in the profitable markets of North America and Europe are now over 50 and are vulnerable to side effects from the drugs that keep them alive, making tolerability more important than in the past. But a key question remains the durability of the treatment, given that many patients will be on HIV medication for decades. So while some doctors will be assured by the 48-week data, others may want to see two- or three-year results. The central worry is the emergence of drug resistance. While no resistance was seen in the 48-week trials, there was a case in an earlier study, although GSK believes this was likely down to failure to take the drugs properly. Regulators are also investigating if dolutegravir might be linked to birth defects, although there is no evidence proving a connection at this stage. ViiV, in which Pfizer and Shionogi have small stakes, plans regulatory submissions for the two-drug combination later this year. If approved, the new combination is expected to be much more widely used than another GSK two-drug regimen called Juluca.
Example Output:
GSK's two-drug HIV treatment proves itself in key tests.